G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Hardware Verification and Validation Engineer

Full-TimeUpdated on 10/23/2026
No salary listed
Mid, Senior
Bachelor's
Bengaluru, Karnataka, India
In Person
Hardware EngineeringHardware Validation & Testing

About the job

Requirements
  • A bachelor's degree in Electronics Engineering, Electrical Engineering, Biomedical Engineering, or a related discipline.
  • 3–5 years of experience in product verification, validation, test engineering, or system testing.
  • Strong understanding of hardware and embedded system testing methodologies.
  • Experience with reliability testing, burn-in testing, and qualification testing.
  • Hands-on experience with laboratory equipment such as oscilloscopes, power supplies, digital multimeters, and data acquisition systems.
  • Experience documenting requirements, test cases, and results using Jama or an equivalent requirements management system.
  • Strong problem-solving, debugging, and root-cause analysis skills.
  • Strong technical documentation and reporting skills.
Responsibilities
  • Execute product-level verification and validation activities for handheld ultrasound systems.
  • Develop, maintain, and execute test plans, test procedures, and verification protocols.
  • Verify system functionality against product and system requirements.
  • Document test execution, results, observations, and defects with complete traceability.
  • Plan and perform reliability qualification testing, including burn-in, thermal, lifecycle, stress and endurance, environmental, and transportation-related tests.
  • Analyze test results and generate reliability reports.
  • Perform ultrasound image-quality testing using industry-standard phantoms.
  • Evaluate image performance, consistency, and system behavior across operating modes.
  • Support image-quality benchmarking and regression testing activities.
  • Develop, update, maintain, and troubleshoot test jigs, fixtures, and automated test setups.
  • Improve test efficiency, repeatability, and coverage through fixture and process enhancements.
  • Perform battery characterization and validation, including scan-time testing, runtime verification, battery lifecycle and aging studies, and charging and discharge performance testing.
  • Generate battery test reports and recommendations.
  • Reproduce field, system, and verification issues reported by development teams or customers.
  • Collect logs, test evidence, measurements, and observations to support root-cause investigations.
  • Work with hardware and software engineers to validate fixes and perform regression testing.
  • Update and maintain correct hardware, firmware, and embedded software revisions on test systems and probes.
  • Ensure testing is performed on approved configurations and released software builds.
  • Support electrical safety, electromagnetic compatibility, and regulatory compliance testing.
  • Coordinate testing activities with internal teams and external certified laboratories.
  • Compile and maintain documentation required for regulatory submissions and audits.
  • Ensure verification records meet Quality Management System requirements.
  • Maintain requirements, test plans, test cases, execution records, and verification reports in Jama.
  • Ensure traceability between requirements, test procedures, test evidence, defects, and validation reports.
  • Generate verification summaries and release documentation packages.
  • Help validate new features, identify and reproduce issues, verify fixes, and provide objective evidence for product release.
Desired Qualifications
  • Experience in medical device development and verification.
  • Familiarity with ultrasound systems and image-quality assessment using phantoms.
  • Knowledge of IEC 60601 electrical safety standards and medical device compliance processes.
  • Experience working with external certification or testing laboratories.
  • Exposure to battery testing, charging systems, and portable medical products.
  • Understanding of quality systems, design controls, and regulated product development environments.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.

Associated Press
Sep 22nd, 2026
GE HealthCare raises quarterly dividend 14% to $0.04 per share for Q3 2026

GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.